HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants

Nature Genetics

Volumn 46, Issue 10, 2014, Pages 1131-1134

  Heap, Graham A ^a,b   Weedon, Michael N ^b   Bewshea, Claire M ^a,b   Singh, Abhey ^a   Chen, Mian ^c   Satchwell, Jack B ^c   Vivian, Julian P ^d   So, Kenji ^a   Dubois, Patrick C ^e   Andrews, Jane M ^f   Annese, Vito ^g   Bampton, Peter ^h   Barnardo, Martin ^c   Bell, Sally ⁱ   Cole, Andy ^j   Connor, Susan J ^k   Creed, Tom ^l   Cummings, Fraser R ^m   D'Amato, Mauro ⁿ   Daneshmend, Tawfique K ^a   Fedorak, Richard N ^o   Florin, Timothy H ^p   Gaya, Daniel R ^q   Greig, Emma ^q   Halfvarson, Jonas ^r   Hart, Alisa ^s   Irving, Peter M ^t   Jones, Gareth ^u   Karban, Amir ^v   Lawrance, Ian C ^w   Lee, James C ^x   Lees, Charlie ^y   Lev Tzion, Raffi ^v   Lindsay, James O ^z   Mansfield, John ^aa   Mawdsley, Joel ^ab   Mazhar, Zia ^ac   Parkes, Miles ^ad   Parnell, Kirstie ^y   Orchard, Timothy R ^b   Radford Smith, Graham ^p,ae,af   Russell, Richard K ^ag   Reffitt, David ^ah   Satsangi, Jack ^v   Silverberg, Mark S ^ai   Sturniolo, Giacomo C ^aj   Tremelling, Mark ^ak   Tsianos, Epameinondas V ^al   Van Heel, David A ^am   Walsh, Alissa ^an   Watermeyer, Gill ^ao   Weersma, Rinse K ^ap   Zeissig, Sebastian ^d   Rossjohn, Jamie ^aq   Holden, Arthur L ^ar   Ahmad, Tariq ^a,b   more..

^a ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EXETER   (United Kingdom)

^c OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d MONASH UNIVERSITY   (Australia)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f ROYAL ADELAIDE HOSPITAL   (Australia)

^g CAREGGI UNIVERSITY HOSPITAL   (Italy)

^h FLINDERS UNIVERSITY   (Australia)

ⁱ ST VINCENT S HOSPITAL   (Australia)

^j ROYAL DERBY HOSPITAL   (United Kingdom)

^k LIVERPOOL HOSPITAL   (Australia)

^l UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^m UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

ⁿ KAROLINSKA INSTITUTE   (Sweden)

^o UNIVERSITY OF ALBERTA   (Canada)

^p UNIVERSITY OF QUEENSLAND   (Australia)

^q GLASGOW ROYAL INFIRMARY   (United Kingdom)

^r TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

^s ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^t ST MARK S HOSPITAL   (United Kingdom)

^u GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^v WESTERN GENERAL HOSPITAL   (United Kingdom)

^w RAMBAM MEDICAL CENTER   (Israel)

^x UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^y CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^z SHAARE ZEDEK MEDICAL CENTER   (Israel)

^aa BARTS HEALTH NHS TRUST   (United Kingdom)

^ab NATIONAL HEALTH SERVICE   (United Kingdom)

^ac CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^ad BASILDON HOSPITAL   (United Kingdom)

^ae IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^af ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^ag ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^ah LEWISHAM AND GREENWICH NHS TRUST   (United Kingdom)

^ai MOUNT SINAI HOSPITAL   (Canada)

^aj UNIVERSITY OF PADOVA   (Italy)

^ak NORFOLK AND NORWICH HOSPITAL   (United Kingdom)

^al UNIVERSITY OF IOANNINA   (Greece)

^am QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^an ST VINCENT S HOSPITAL   (Australia)

^ao UNIVERSITY OF CAPE TOWN   (South Africa)

^ap UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^aq UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^ar International Serious Adverse Event Consortium   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; HLA DQA1 ANTIGEN; HLA DRB1 ANTIGEN; MERCAPTOPURINE; HLA DQ ANTIGEN; HLA-DQA1 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; PROTEIN BINDING;

ALLELE; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CONTROLLED STUDY; CROHN DISEASE; DRUG EXPOSURE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; PANCREATITIS; PREVALENCE; PRIORITY JOURNAL; SMOKING; ULCERATIVE COLITIS; CHEMICAL STRUCTURE; CHEMICALLY INDUCED; CHEMISTRY; CLINICAL TRIAL; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HAPLOTYPE; INFLAMMATORY BOWEL DISEASES; METABOLISM; MULTICENTER STUDY; PROTEIN TERTIARY STRUCTURE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

6-MERCAPTOPURINE; AZATHIOPRINE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HAPLOTYPES; HLA-DQ ALPHA-CHAINS; HLA-DRB1 CHAINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PANCREATITIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RISK FACTORS;

EID: 84922070460     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3093     Document Type: Article

References (36)

1. Health and Social Care Information Centre. Quarterly Prescription Cost Analysis, England (UK Government Statistical Service, London, 2013).
2. Prefontaine, E., Sutherland, L.R., Macdonald, J.K. & Cepoiu, M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 1, CD000067 (2009).
3. Timmer, A., MacDonald, J.W., Tsoulis, D.J. & Macdonald, J.K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 9, CD000478 (2012).
4. Cosnes, J. et al. Early administration of azathioprine vs conventional management of Crohn's disease: a randomized controlled trial. Gastroenterology 145, 758-765 (2013).
5. Chaparro, M. et al. Safety of thiopurine therapy in infammatory bowel disease: long-term follow-up study of 3931 patients. Infamm. Bowel Dis. 19, 1404-1410 (2013).
6. Gearry, R.B., Barclay, M.L., Burt, M.J., Collett, J.A. & Chapman, B.A. Thiopurine drug adverse effects in a population of New Zealand patients with infammatory bowel disease. Pharmacoepidemiol. Drug Saf. 13, 563-567 (2004).
7. Daly, A.K. et al. HLA-B∗5701 genotype is a major determinant of drug-induced liver injury due to fucloxacillin. Nat. Genet. 41, 816-819 (2009).
8. Mallal, S. et al. HLA-B∗5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008).
9. Gallagher, R.M. et al. Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. PLoS ONE 6, e28096 (2011).
10. Wellcome Trust Case Control Consortium. Genome-wide association study of 14, 000 cases of seven common diseases and 3, 000 shared controls. Nature 447, 661-678 (2007).
11. Barrett, J.C. et al. Genome-wide association study of ulcerative colitis identifes three new susceptibility loci, including the HNF4A region. Nat. Genet. 41, 1330-1334 (2009).
12. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 467, 1061-1073 (2010).
13. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G.R. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat. Genet. 44, 955-959 (2012).
14. Jia, X. et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS ONE 8, e64683 (2013).
15. Ahmad, T. et al. The molecular classifcation of the clinical manifestations of Crohn's disease. Gastroenterology 122, 854-866 (2002).
16. Tilney, N.L., Collins, J.J. & Wilson, R.E. Hemorrhagic pancreatitis. A fatal complication of renal transplantation. N. Engl. J. Med. 274, 1051-1057 (1966).
17. Nogueira, J.R. & Freedman, M.A. Acute pancreatitis as a complication of Imuran therapy in regional enteritis. Gastroenterology 62, 1040-1041 (1972).
18. Marinaki, A.M. et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 14, 181-187 (2004).
19. Illing, P.T., Vivian, J.P., Purcell, A.W., Rossjohn, J. & McCluskey, J. Human leukocyte antigen-associated drug hypersensitivity. Curr. Opin. Immunol. 25, 81-89 (2013).
20. Kindmark, A. et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8, 186-195 (2008).
21. Spraggs, C.F. et al. HLA-DQA1∗02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol. 29, 667-673 (2011).
22. Illing, P.T. et al. Immune self-reactivity triggered by drug-modifed HLA-peptide repertoire. Nature 486, 554-558 (2012).
23. Badalov, N. et al. Drug-induced acute pancreatitis: an evidence-based review. Clin. Gastroenterol. Hepatol. 5, 648-661 (2007).
24. Grant, R.L. Converting an odds ratio to a range of plausible relative risks for better communication of research fndings. Br. Med. J. 348, f7450 (2014).
25. Oliphant, A., Barker, D.L., Stuelpnagel, J.R. & Chee, M.S. BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. Biotechniques (suppl.), 56-58 (2002).
26. Goldstein, J.I. et al. zCall: a rare variant caller for array-based genotyping: genetics and population analysis. Bioinformatics 28, 2543-2545 (2012).
27. Barrett, J.C. et al. Genome-wide association defnes more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40, 955-962 (2008).
28. Anderson, C.A. et al. Meta-analysis identifes 29 additional ulcerative colitis risk loci, increasing the number of confrmed associations to 47. Nat. Genet. 43, 246-252 (2011).
29. Yang, J., Lee, S.H., Goddard, M.E. & Visscher, P.M. GCTA: a tool for genome-wide complex trait analysis. Am. J. Hum. Genet. 88, 76-82 (2011).
30. Manichaikul, A. et al. Robust relationship inference in genome-wide association studies. Bioinformatics 26, 2867-2873 (2010).
31. Sebastiani, P. et al. Retraction. Science 333, 404 (2011).
32. Li, Y., Willer, C.J., Ding, J., Scheet, P. & Abecasis, G.R. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet. Epidemiol. 34, 816-834 (2010).
33. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559-575 (2007).
34. Scally, S.W. et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J. Exp. Med. 210, 2569-2582 (2013).
35. Morris, G.M. et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor fexibility. J. Comput. Chem. 30, 2785-2791 (2009).
36. Trott, O. & Olson, A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, effcient optimization, and multithreading. J. Comput. Chem. 31, 455-461 (2010).